secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001600620-26-000035
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia to acquire Kezar for $6.955/share plus CVR; tender offer by April 13
----------------------------------------------------------------------------

- Aurinia (AUPH) to acquire Kezar (KZR) for $6.955 per share in cash plus one non-transferable CVR.
- CVR entitles holders to potential payments from zetomipzomib milestones, Everest/Enodia proceeds, and Kezar's net cash over $50M.
- Kezar's lead asset zetomipzomib is a first-in-class immunoproteasome inhibitor for autoimmune hepatitis and lupus.
- Tang Capital Partners (9% holder) signed support agreement to tender shares; deal expected to close Q2 2026.
- Kezar's board unanimously approved; TD Cowen and Cooley advised Kezar.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000035/0001600620-26-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000035/auph-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001600620-26-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer